Table 3.
Significant factors correlated with changes in clinical symptoms, general function, and cognitive function.
| Outcome variablesChange in | Significant factors | R2 | Beta | P | 95% CI | |
|---|---|---|---|---|---|---|
| Lower | Upper | |||||
| PANSS | ||||||
| Total | Baseline PANSS total | 0.808 | 0.846 | <0.001** | 0.653 | 1.040 |
| Antipsychotics | −0.467 | 0.002* | −0.750 | −0.184 | ||
| Positive symptoms | Baseline PANSS positive | 0.830 | 0.893 | <0.001** | 0.713 | 1.074 |
| Antipsychotics | −0.071 | 0.042* | −0.139 | −0.003 | ||
| Negative symptoms | Sex | 0.841 | 4.503 | 0.002* | 1.830 | 7.175 |
| DUP | −0.669 | 0.010* | −1.156 | −0.181 | ||
| Baseline PANSS negative | 0.736 | <0.001** | 0.552 | 0.919 | ||
| Antipsychotics | −0.214 | <0.001** | −0.314 | −0.114 | ||
| General symptoms | Baseline PANSS general | 0.778 | 0.844 | <0.001** | 0.637 | 1.052 |
| Antipsychotics | −0.163 | 0.036* | −0.314 | −0.012 | ||
| GAF | Sex | 0.597 | −8.979 | 0.024* | −16.647 | −1.312 |
| Baseline GAF score | 0.464 | <0.001** | 0.247 | 0.680 | ||
| TMT-A (n = 23) | Baseline TMT-A | 0.448 | 0.698 | <0.001** | 0.365 | 1.031 |
| TMT-B (n = 22) | Change in MMN amplitude at Fz | 0.891 | 9.057 | 0.023* | 1.426 | 16.688 |
| IQ | −0.683 | 0.016* | −1.222 | −0.144 | ||
| Baseline TMT-B | 0.880 | <0.001** | 0.708 | 1.051 | ||
| TMT B/A (n = 22) | Baseline TMT B/A | 0.855 | 0.992 | <0.001** | 0.801 | 1.182 |
PANSS, Positive and Negative Syndrome Scale; DUP, duration of untreated psychosis; GAF, Global Assessment of Functioning; TMT-A, Trail Making Test part A; TMT-B, Trail Making Test part B; TMT B/A, ratio score of Trail Making Test part B to part A; MMN, Mismatch negativity.
*The mean difference is significant at the 0.05 level.
**The mean difference is significant at the 0.005 level.